DE69129697T2 - Aus mehreren domänen bestehende hämatopoese-stimulatoren - Google Patents

Aus mehreren domänen bestehende hämatopoese-stimulatoren

Info

Publication number
DE69129697T2
DE69129697T2 DE69129697T DE69129697T DE69129697T2 DE 69129697 T2 DE69129697 T2 DE 69129697T2 DE 69129697 T DE69129697 T DE 69129697T DE 69129697 T DE69129697 T DE 69129697T DE 69129697 T2 DE69129697 T2 DE 69129697T2
Authority
DE
Germany
Prior art keywords
hematopoese
stimulators
multiple domain
domain
hematopoietin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69129697T
Other languages
English (en)
Other versions
DE69129697D1 (de
DE69129697T3 (de
Inventor
Paul Schendel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetics Institute LLC
Original Assignee
Genetics Institute LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24298530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69129697(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genetics Institute LLC filed Critical Genetics Institute LLC
Publication of DE69129697D1 publication Critical patent/DE69129697D1/de
Publication of DE69129697T2 publication Critical patent/DE69129697T2/de
Application granted granted Critical
Publication of DE69129697T3 publication Critical patent/DE69129697T3/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
DE69129697T 1990-08-29 1991-08-29 Aus mehreren domänen bestehende hämatopoese-stimulatoren Expired - Fee Related DE69129697T3 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57500390A 1990-08-29 1990-08-29
PCT/US1991/006186 WO1992004455A1 (en) 1990-08-29 1991-08-29 Multidomain hematopoiesis stimulators

Publications (3)

Publication Number Publication Date
DE69129697D1 DE69129697D1 (de) 1998-08-06
DE69129697T2 true DE69129697T2 (de) 1999-01-07
DE69129697T3 DE69129697T3 (de) 2004-01-29

Family

ID=24298530

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69129697T Expired - Fee Related DE69129697T3 (de) 1990-08-29 1991-08-29 Aus mehreren domänen bestehende hämatopoese-stimulatoren

Country Status (11)

Country Link
US (1) US5883230A (de)
EP (1) EP0546124B2 (de)
JP (1) JP3149182B2 (de)
AT (1) ATE167896T1 (de)
AU (1) AU651152B2 (de)
CA (1) CA2089553C (de)
DE (1) DE69129697T3 (de)
DK (1) DK0546124T4 (de)
ES (1) ES2118756T5 (de)
GR (1) GR3027790T3 (de)
WO (1) WO1992004455A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5718893A (en) * 1984-04-15 1998-02-17 Foster; Preston F. Use of G-CSF to reduce acute rejection
US5662896A (en) * 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
WO1992006116A1 (en) * 1990-09-28 1992-04-16 Ortho Pharmaceutical Corporation Hybrid growth factors
US5738849A (en) * 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
US7091319B1 (en) 1992-11-24 2006-08-15 Bauer S Christopher IL-3 variant hematopoiesis fusion protein
US6413509B1 (en) 1992-11-24 2002-07-02 S. Christopher Bauer Methods of ex-vivo expansion of hematopoietic cells using interleukin-3 mutant polypeptides with other hematopoietic growth factors
US6361977B1 (en) 1992-11-24 2002-03-26 S. Christopher Bauer Methods of using multivariant IL-3 hematopoiesis fusion protein
US6057133A (en) * 1992-11-24 2000-05-02 G. D. Searle Multivariant human IL-3 fusion proteins and their recombinant production
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US5501962A (en) * 1993-06-21 1996-03-26 G. D. Searle & Co. Interleuken-3 (IL-3) human/murine hybrid polypeptides and recombinant production of the same
US5536495A (en) * 1994-04-15 1996-07-16 Foster; Preston F. Use of G-CSF to reduce acute rejection
WO1995028427A1 (en) * 1994-04-15 1995-10-26 Imclone Systems Incorporated Chimeric interleukin-3/mutein interleukin-6 lymphokine
US5582821A (en) * 1994-07-22 1996-12-10 Genetics Institute, Inc. Methods for treating bleeding disorders
AU4658596A (en) 1995-02-03 1996-08-21 G.D. Searle & Co. Novel c-mpl ligands
WO1996034016A1 (fr) * 1995-04-26 1996-10-31 Kyowa Hakko Kogyo Co., Ltd. Nouveaux polypeptides
US6887461B1 (en) 1998-10-26 2005-05-03 Genetics Institute, Llc Method of using IL-11 for treating mucositis
US6540993B1 (en) 1995-06-27 2003-04-01 Wyeth Method of treating inflammatory bowel disease using a topical formulation of IL-11
US6066318A (en) 1995-10-05 2000-05-23 G.D. Searle & Co. Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors
US6967092B1 (en) 1996-10-25 2005-11-22 Mc Kearn John P Multi-functional chimeric hematopoietic receptor agonists
US6884419B1 (en) 1996-12-23 2005-04-26 Kyowa Hakko Kogyo, Co., Ltd. hG-CSF fusion polypeptide having c-mpl activity, DNA coding for same and methods of treating anemia using same
US6187564B1 (en) 1997-07-10 2001-02-13 Beth Israel Deaconess Medical Center DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics
US6242570B1 (en) * 1997-07-10 2001-06-05 Beth Israel Deaconess Medical Center Production and use of recombinant protein multimers with increased biological activity
US6953777B2 (en) 1999-03-11 2005-10-11 Genetics Indtitute LLC Use of interleukin-11 to prevent immune-mediated cytotoxicity
CA2379354A1 (en) 1999-07-15 2001-01-25 Genetics Institute, Inc. Formulations for il-115
BR0013231A (pt) 1999-08-09 2002-07-23 Lexigen Pharm Corp Complexos citocina-anticorpo múltiplos
EP1731531B1 (de) * 1999-08-09 2012-05-30 Merck Patent GmbH Mehrere Zytokin-Antikörper Komplexe
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
US6646110B2 (en) * 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
US6831158B2 (en) * 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
NZ530545A (en) * 2001-07-11 2006-10-27 Maxygen Holdings Ltd Specific conjugates comprising a polypeptide exhibiting G-CSF activity and a non-polypeptide moiety
US6982080B2 (en) 2002-03-15 2006-01-03 Wyeth Hydroxyethyl starch—containing polypeptide compositions
EP1648931B1 (de) 2003-07-21 2011-02-09 Transgene S.A. Multifunktionelle cytokine
US7220407B2 (en) 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
AU2005306894B2 (en) 2004-11-05 2011-11-24 Northwestern University Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders
BRPI0611221A2 (pt) 2005-06-01 2010-08-24 Maxygen Holdings Ltd polipeptÍdeos de g-csf peguilados e mÉtodos de produÇço dos mesmos
KR200462405Y1 (ko) 2010-10-18 2012-09-11 서상기 선물용 인형다발
LT6161B (lt) * 2013-09-27 2015-06-25 Uab Profarma Granuliocitų kolonijas stimuliuojančio faktoriaus sulieti baltymai su kitais augimo faktoriais, optimaliai su kamieninių ląstelių faktoriumi, ir jų gavimo būdas

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2534222B2 (ja) * 1982-05-12 1996-09-11 プレジデント アンド フエロウズ オブ ハ−バ−ド カレツジ 混成タンパク質生産用融合遺伝子
WO1985004420A1 (en) * 1984-03-29 1985-10-10 Takeda Chemical Industries, Ltd. Novel dna and its use
US4691009A (en) * 1984-12-26 1987-09-01 Repligen Corporation Hybrid proteins produced by an ultrahigh prokaryotic expression system
EP0205404B1 (de) * 1985-06-11 1992-07-15 Ciba-Geigy Ag Hybrid-Interferone
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
JPS63267278A (ja) * 1986-03-14 1988-11-04 Toray Ind Inc インタ−フエロン結合体を暗号化する塩基配列
US5032395A (en) * 1986-07-14 1991-07-16 Genetics Institute, Inc. Method of inducing leukocytosis with a combination of IL-3 and GM-CSF
NZ221298A (en) * 1986-08-01 1990-07-26 Commw Scient Ind Res Org A recombinant vaccine comprising an antigenic polypeptide component together with a lymphokine component
EP0257406B2 (de) * 1986-08-06 1998-08-12 Ajinomoto Co., Inc. Rekombinanter B-Zell-Differenzierungsfaktor
JPH082315B1 (de) * 1987-05-29 1996-01-17 Sagami Chuo Kagaku Kenkyusho
WO1990001039A1 (en) * 1988-07-20 1990-02-08 Immunex Corporation Nonglycosylated human interleukin-3 compositions
JPH02275714A (ja) * 1989-01-09 1990-11-09 Kao Corp 表面処理重曹粒子及びこれを含有する成型製剤
US5032396A (en) * 1989-02-17 1991-07-16 Immunex Corporation IL-7 to stimulate platelet production
CA2014473A1 (en) * 1989-04-14 1990-10-14 Hong-Ji Xu Purified, highly specific antibodies against gene products including retinoblastoma and method
WO1990012877A1 (en) * 1989-04-19 1990-11-01 Cetus Corporation Multifunctional m-csf proteins and genes encoding therefor
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
CA2035868A1 (en) * 1989-07-06 1991-01-07 Richard C. Svrluga Hybrid molecules
US5073627A (en) * 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
ES2055445T3 (es) * 1989-08-22 1994-08-16 Immunex Corp Proteinas de fusion que comprenden gm-csf e il-3.
US5108910A (en) * 1989-08-22 1992-04-28 Immunex Corporation DNA sequences encoding fusion proteins comprising GM-CSF and IL-3
US5215895A (en) * 1989-11-22 1993-06-01 Genetics Institute, Inc. Dna encoding a mammalian cytokine, interleukin-11
US5238823A (en) * 1990-08-22 1993-08-24 Veterinary Infectious Disease Organization Interleukin-2-leukotoxin gene fusions and uses thereof
WO1992006116A1 (en) * 1990-09-28 1992-04-16 Ortho Pharmaceutical Corporation Hybrid growth factors

Also Published As

Publication number Publication date
EP0546124A1 (de) 1993-06-16
AU651152B2 (en) 1994-07-14
ES2118756T5 (es) 2004-01-16
CA2089553C (en) 2000-06-27
GR3027790T3 (en) 1998-11-30
ES2118756T3 (es) 1998-10-01
WO1992004455A1 (en) 1992-03-19
EP0546124B1 (de) 1998-07-01
JP3149182B2 (ja) 2001-03-26
EP0546124B2 (de) 2003-04-23
DK0546124T3 (da) 1998-10-26
DK0546124T4 (da) 2003-05-19
AU8917491A (en) 1992-03-30
JPH06500116A (ja) 1994-01-06
US5883230A (en) 1999-03-16
CA2089553A1 (en) 1992-03-01
ATE167896T1 (de) 1998-07-15
DE69129697D1 (de) 1998-08-06
DE69129697T3 (de) 2004-01-29

Similar Documents

Publication Publication Date Title
DE69129697D1 (de) Aus mehreren domänen bestehende hämatopoese-stimulatoren
IT1212114B (it) Molla.
CY2000009I1 (el) Συντετηγμενες πρωτεïνες με μερη ανοσοσφαιρινης, η παρασκευη και η χρηση τους
ATE106220T1 (de) Pediculus-verbindungselement.
ES510011A0 (es) "un metodo de crear un microorganismo capaz de producir una proteina predeterminada por expresion".
ES262584Y (es) "bisagra abatible de una sola pieza de material sintetico".
SE9301270D0 (sv) Biosensor
DE3874088T2 (de) Vliesstoff aus polyallylensulfid.
DE68900262D1 (de) Verbinden polyolefinischer teile durch schmelzung.
MX172742B (es) Compuestos de piridina 2,6 substituidos
DE130628T1 (de) Transparentes echtzeit-serien/echoplex-interface.
IT8723057A0 (it) Gasificatore di fusione.
DE3483830D1 (de) Polyesteramid-schmelzkleber.
IT8220208A0 (it) Respingente a molla.
IT8320707A0 (it) Diidro-benzofurano derivati adattivita' erbicida.
DE59003899D1 (de) Klebstoff zum Verbinden von Formteilen aus Polycarbonat-Kunststoffen.
ATA341884A (de) Kunststoff-blattfeder
DE3481959D1 (de) Elektrodengegenstand.
DK284489D0 (da) Fusionsproteiner
IT1140155B (it) Molla
IT8821827A0 (it) Utensile con molla.
IT8459364V0 (it) Poltrona pieghevole "capo horn".
IT1139769B (it) Termoregolatore a molla di bourdon perfezionato
IT8103803V0 (it) "cerniera elastica per occhiali con molla a spinta".
IT8818104A0 (it) Serra.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: GENETICS INSTITUTE, LLC, CAMBRIDGE, MASS., US

8366 Restricted maintained after opposition proceedings
8339 Ceased/non-payment of the annual fee